Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach

Keith T. Flaherty, MD, is associate professor of medicine at Harvard Medical School as well as director of the Henri and Belinda Termeer Center for Targeted Therapies and director of clinical research at Massachusetts General Hospital Cancer Center in Boston.

Dr. Flaherty received a bachelor of science from Yale University and medical degree from Johns Hopkins University. He trained in internal medicine at Brigham and Women's Hospital and completed a fellowship in medical oncology at the University of Pennsylvania, where he continued on as faculty before moving to Massachusetts General Hospital and Harvard Medical School.

Dr. Flaherty is the deputy chair for Biomarker Science and chair of the Developmental Therapeutics Committee for the Eastern Cooperative Oncology Group. He is a senior editor for Clinical Cancer Research. He is a charter member of the National Cancer Institute Developmental Therapeutics Study Section. Additionally, Dr. Flaherty is president-elect of the Society for Melanoma Research and is on the board of trustees for the Cancer Education Consortium.

With a career-long focus in therapeutic research in advanced melanoma, Dr. Flaherty has led the investigation of many of the first molecular targeted therapies brought forward in light of emerging molecular biology discoveries regarding the somatic genetic underpinnings of melanoma. He has also contributed greatly to the clinical development and associated translational research with numerous investigational targeted therapies, including the first effective targeted therapies for metastatic melanoma. His work has been published in a number of peer-reviewed publications, including Clinical Cancer Research, New England Journal of Medicine, Nature, and Lancet Oncology, and he is on the editorial boards of Oncologist, Journal of Translational Medicine, and Journal of Clinical Oncology, and he is a senior editor for Clinical Cancer Research and scientific editor for Cancer Discovery.

Michael Davies, MD, PhD, is deputy chairman and associate professor in the department of Melanoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, with a joint appointment in the department of Systems Biology.
 
Dr. Davies earned his medical and doctorate degrees from the University of Texas Health Science Center in Houston. He completed his clinical residency training in internal medicine at Massachusetts General Hospital in Boston and his medical oncology fellowship at the University of Texas MD Anderson Cancer Center.
 
Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and the molecular pathogenesis brain metastases. He is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research, Society for Melanoma Research, and SWOG.
 
Dr. Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute, ASCO, Melanoma Research Alliance, and Melanoma Research Foundation. He has served as the principal investigator of several clinical trials for patients with metastatic melanoma and has authored or co-authored research in peer-reviewed journals including Cell, Cancer Cell, Cancer Research, and Clinical Cancer Research. Dr. Davies is a member of the Melanoma Research Foundation Breakthrough Consortium and the International Melanoma Working Group, and he is the co-director of the MD Anderson Melanoma Moon Shot Team and the MD Anderson MelCore, the largest clinically annotated melanoma tissue bank in the world.

Janice M. Mehnert, MD, is director of the Developmental Therapeutics Unit at Rutgers Cancer Institute of New Jersey and a member of the Melanoma and Soft Tissue Oncology Program. She is also an associate professor of medicine at Rutgers Robert Wood Johnson Medical School.
 
Dr. Mehnert received her medical degree from Rutgers Robert Wood Johnson Medical School. She completed her residency training in internal medicine at the Mount Sinai Hospital, New York, followed by a fellowship in medical oncology and hematology at the Yale Cancer Center. She began her career at Rutgers Cancer Institute of New Jersey/Rutgers Robert Wood Johnson Medical School.
 
At a national level, Dr. Mehnert is part of the Melanoma Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, where she works with other investigators to develop clinical trials for patients with melanoma. She is a member of the American Society Clinical Oncology Education Committee for Melanoma and Skin Cancers. Her clinical research focuses on novel therapies for all types of tumors, especially melanoma and sarcoma, and involves the development of both targeted and immunotherapies. Her broad clinical research experience spans industry-sponsored, investigator-initiated, and cooperative group studies.
 
Dr. Mehnert is the author or co-author of multiple peer-reviewed articles and book chapters and has been awarded numerous peer-reviewed national and private foundation grants to support her work. She has published in such prestigious authorities as Cancer Discovery, Journal of Clinical Oncology, and Clinical Cancer Research, having served on the editorial board of the latter.